Specific activity of concentrated and purified cell culture rabies vaccine (CPCRV) from the strain Vnukovo -32-107 in an experiment with therapeutical immunization of humans.
Reactogenicity and specific activity of three series of concentrated and purified cell culture rabies vaccine (CPCRV) were studied in an experiment of therapeutical immunization of 300 human subjects bitten by domestic animals, category "C". CPCRV was well tolerated; when administered intramuscularly, it did not provoke local reactions, while general reactions, such as temporary headaches and indisposition, were observed in 4% of cases. Intradermal revaccination with CPCRV was followed by local reactions in 73.6% of cases. Such a reaction can be regarded as a cutaneous allergic test. Coded paired sera of 263 subjects were examined in the neutralization reaction on mice. After primary intramuscular immunization, antibody titres were found to be very low. Relatively high titres of antibodies and 100% seroconversion were recorded after a single intramuscular or intradermal revaccination with CPCRV. Relatively high antibody titres and 100% seroconversion also resulted from treble, and especially quadruple primary intramuscular immunization using a dose of 1.5 ml on days 0, 8, 16, 24 or 0, 8, 16 and 32. When treating bites of non-dangerous localization, CPCRV can be administered in a dose of 1.5 ml at a time on days 0, 7 15, 30 and 60 (5 injections in total). The scheme of combined vaccinations using CPCRV and antirabies gamma-globulin requires exploration.